President Donald Trump is set to fire FDA Commissioner Marty Makary, The Wall Street Journal reports, citing sources familiar ...

Daiichi Sankyo is poised to report significantly lower full-year profit for fiscal year 2025, primarily due to a 95 billion ...

After losing the top spot in March to Johnson & Johnson’s immunology drug Tremfya, AbbVie’s rival med Skyrizi is back as the ...

With its largest-ever acquisition, Angelini gains 24-year-old Catalyst, which was listed on the Nasdaq in 2006. Catalyst ...

With an FDA decision date looming for its Duchenne muscular dystrophy (DMD) treatment deramiocel, Capricor Therapeutics has filed a ...

Summit Therapeutics' closely watched PD-1xVEGF study surprisingly missed its mark at an interim analysis. | Summit's ...

GSK is teaming up with “Modern Family” stars Julie Bowen and Ty Burrell to help get out the messaging: “ask to be sure” about ...

In the latest update to COVID and vaccine-related discourse bubbling up at the FDA, agency officials have recently blocked ...

Gilead raised its previous guidance of $800 million in revenues from the long-acting PrEP injectable Yeztugo based on a ...

After a surprise rejection at the beginning of 2026, the FDA has agreed to reconsider a T-cell therapy based on the same ...

Since it was established nearly a year ago by the FDA, the Commissioner’s National Priority Voucher (CNPV) program has been ...

Since the start of the decade, Eli Lilly has committed to spend more than $50 billion to bolster its United States ...